# Ono Pharmaceutical Co., Ltd.: Phase 1 study closed enrollment, 32 enrolled (Metastatic Pancreatic Cancer)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Ono Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer |
| NCT ID | NCT06532344 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention types | drug |
| Target enrollment | 32 |
| Site countries | Japan |
| Posted | 2024-08-01 |
| Planned start | 2021-07-30 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-07 |
| Last update posted | 2026-10-07 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06532344). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.